The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index; none of the 18 sources its claims cite is checked for support yet.
Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy
Open accessAbstract
Background Gene therapy with elivaldogene autotemcel (eli-cel) consisting of autologous CD34+ cells transduced with lentiviral vector containing ABCD1 complementary DNA (Lenti-D) has shown efficacy in clinical studies for the treatment of cerebral adrenoleukodystrophy. However, the risk of oncogenesis with eli-cel is unclear. Methods We performed integration-site analysis, genetic studies, flow cytometry, and morphologic studies in peripheral-blood and bone marrow samples from patients who received eli-cel therapy in two completed phase 2–3 studies (ALD-102 and ALD-104) and an ongoing follow-up study (LTF-304) involving the patients in both ALD-102 and ALD-104. Results Hematologic cancer developed in 7 of 67 patients after the receipt of eli-cel (1 of 32 patients in the ALD-102 study and 6 of 35 patients in the ALD-104 study): myelodysplastic syndrome (MDS) with unilineage dysplasia in 2 patients at 14 and 26 months; MDS with excess blasts in 3 patients at 28, 42, and 92 months; MDS in 1 patient at 36 months; and acute myeloid leukemia (AML) in 1 patient at 57 months. In the 6 patients with available data, predominant clones contained lentiviral vector insertions at multiple loci, including at either MECOM–EVI1 (MDS and EVI1 complex protein EVI1 [ecotropic virus integration site 1], in 5 patients) or PRDM16 (positive regulatory domain zinc finger protein 16, in 1 patient). Several patients had cytopenias, and most had vector insertions in multiple genes within the same clone; 6 of the 7 patients also had somatic mutations ( KRAS , NRAS , WT1 , CDKN2A or CDKN2B , or RUNX1 ), and 1 of the 7 patients had monosomy 7. Of the 5 patients with MDS with excess blasts or MDS with unilineage dysplasia who underwent allogeneic hematopoietic stem-cell transplantation (HSCT), 4 patients remain free of MDS without recurrence of symptoms of cerebral adrenoleukodystrophy, and 1 patient died from presumed graft-versus-host disease 20 months after HSCT (49 months after receiving eli-cel). The patient with AML is alive and had full donor chimerism after HSCT; the patient with the most recent case of MDS is alive and awaiting HSCT. Conclusions Hematologic cancer developed in a subgroup of patients who were treated with eli-cel; the cases are associated with clonal vector insertions within oncogenes and clonal evolution with acquisition of somatic genetic defects. (Funded by Bluebird Bio; ALD-102, ALD-104, and LTF-304 ClinicalTrials.gov numbers, NCT01896102 , NCT03852498 , and NCT02698579 , respectively.)
Overview
CoChat Summary
Written by AI from the paper’s full text.
TL;DR
In two completed phase 2–3 studies and long-term follow-up, 7 of 67 patients treated with elivaldogene autotemcel (eli-cel) for cerebral adrenoleukodystrophy developed hematologic cancer, associated with clonal lentiviral vector insertions in MECOM or PRDM16 and acquired somatic defects. The authors conclude that this oncogenic risk must be weighed against the severity of cerebral adrenoleukodystrophy and that monitoring and future vector design should be informed by these cases.
Key findings
- Hematologic cancer developed in 7 of 67 eli-cel recipients (10%) over 338 person-years: incidence rate 2.1 per 100 person-years (95% CI, 0.8 to 4.2); 1 of 32 patients in ALD-102 (0.5 per 100 person-years; 95% CI, 0 to 2.5) and 6 of 35 in ALD-104 (5.2 per 100 person-years; 95% CI, 1.9 to 10.9).
- Diagnoses were MDS with unilineage dysplasia in 2 patients at 14 and 26 months; MDS with excess blasts in 3 at 28, 42, and 92 months; MDS in 1 at 36 months; and AML in 1 at 57 months.
- In the 6 patients with available data, predominant clones contained lentiviral vector insertions at multiple loci, including MECOM–EVI1 in 5 patients and PRDM16 in 1; 6 of 7 patients also had somatic mutations (KRAS, NRAS, WT1, CDKN2A or CDKN2B, or RUNX1), and 1 of 7 had monosomy 7.
- Of 5 patients with MDS who underwent allogeneic HSCT, 4 remain free of MDS without recurrence of cerebral adrenoleukodystrophy symptoms, and 1 died from presumed graft-versus-host disease 20 months after HSCT (49 months after eli-cel); the AML patient is alive with full donor chimerism, and the most recent MDS patient is alive awaiting HSCT.
Methods
- Integration-site analysis, genetic studies, flow cytometry, and morphologic studies were performed on peripheral-blood and bone marrow samples from patients who received eli-cel in two completed phase 2–3 studies (ALD-102 and ALD-104) and an ongoing follow-up study (LTF-304).
- A total of 67 patients received eli-cel infusion (32 in ALD-102 and 35 in ALD-104); analyses included integration-site analysis, vector copy number, targeted sequencing with the Rapid Heme Panel, gene expression studies, chromosome analysis, fluorescence in situ hybridization, and flow cytometry.
- The main analysis characterized clinicopathological and genetic features of hematologic cancer cases as of April 25, 2024, with incidence rates and event-free survival reported.
Limitations
- The paper states that whether differences in mobilization and chemotherapy regimens played a role remains unclear, that additional unknown factors appeared to play a role in cancer development, and that persistent oligoclonality testing was not reliably predictive of transformation.
- The paper states that ongoing follow-up is critical to understanding longer-term safety and efficacy.
- Evident from the text: only 7 cancer cases were available, there was no randomized comparator, follow-up duration differed between ALD-102 and ALD-104, the seventh case had limited available data and was undergoing more-detailed investigation, and incidence estimates had wide confidence intervals.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
42 Own result · 7 Check pending · 7 Own interpretation · 3 No full text of the sources · 1 Not checked yet
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Hematologic cancer developed in 7 of 67 patients after the receipt of eli-cel”
- Also stated in: § PATIENTS · plain
“Hematologic cancer developed in 7 patients (incidence rate, 2.1 per 100 person-years [95% CI, 0.8 to 4.2]; 338 person-years of total follow-up)”
- Also stated in: § DISCUSSION · plain
“among the 67 patients treated with eli-cel, 7 patients (10%) have received a diagnosis of hematologic cancer”
§ Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy > Abstract > RESULTS
plainn = 7- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § PATIENTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As of April 25, 2024, the probability of event-free survival (survival without major functional disabilities, hematologic cancer, or rescue-cell administration or allogeneic hematopoietic stem-cell transplantation) at 4 years was 81.0% (95% confidence interval [CI], 68.8 to 88.8)”
§ Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy > RESULTS > PATIENTS
plainn = 67- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All seven patients, as compared with 35% of patients without hematologic cancer, had current oligoclonality.”
§ Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy > RESULTS > INTEGRATION-SITE ANALYSIS AND CLONAL ANALYSES
plainstates an associationn = 7- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“1 who had been treated in the ALD-102 study (incidence rate, 0.5 per 100 person-years [95% CI, 0 to 2.5]; 222 person-years of follow-up)”
§ Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy > RESULTS > PATIENTS
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Hematologic cancer developed in 7 patients (incidence rate, 2.1 per 100 person-years [95% CI, 0.8 to 4.2]; 338 person-years of total follow-up)”
- Also stated in: § DISCUSSION · plain
“incidence rate, 2.1 per 100 person-years; 95% CI, 0.8 to 4.2”
§ Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy > RESULTS > PATIENTS
plainn = 7- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § DISCUSSION · plain
- Probably not a substantial claim. 1
- It may state two separate claims as one. 21
Create a free account to see these claims.
Create a free account to see these assumptions.
34 more claims
Create a free account to see all 60 claims and to verify the 11 references still open.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As reported by Duncan et al., in ALD-104, six cases of hematologic cancer have been recorded in either the 24-month or the long-term follow-up study (five cases of MDS and one case of acute myeloid leukemia).”
From Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy (2024) · cites this paper as [20]
In the citing paper
“On the other hand, it is useful to note that no other studies using LVVs across multiple disease applications have to date reported mutagenic events and that none of these have used LTR regulatory sequences to regulate transgene expression, rather using cellular or derivative cellular elements.59”
From Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy (2025) · cites this paper as [59]
Citations
Cites
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276
Ott, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Montini, E., Cesana, D., Schmidt, M., Sanvito, F., Ponzoni, M., Bartholomae, C. C., Sergi, L. S., Benedicenti, F., Ambrosi, A., Serio, C. D., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1216 · Cited by 711
Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia
Thompson, A. A., Walters, M. C., Kwiatkowski, J., Rasko, J. E. J., Ribeil, J.-A., Hongeng, S., Magrin, E., Schiller, G. J., Payen, E., Semeraro, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705342 · Cited by 684
Moser, H. W., Mahmood, A., & Raymond, G. V. (2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0421 · Cited by 663
Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy
Eichler, F., Duncan, C., Musolino, P. L., Orchard, P. J., De Oliveira, S., Thrasher, A. J., Armant, M., Dansereau, C., Lund, T. C., Miller, W. P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700554 · Cited by 604
Self-citationClonal analysis of lineage fate in native haematopoiesis
Rodriguez-Fraticelli, A. E., Wolock, S. L., Weinreb, C. S., Panero, R., Patel, S. H., Jankovic, M., Sun, J., Calogero, R. A., Klein, A. M., & Camargo, F. D. (2018) · Nature · doi:10.1038/nature25168 · Cited by 596
Montini, E., Cesana, D., Schmidt, M., Sanvito, F., Bartholomae, C. C., Ranzani, M., Benedicenti, F., Sergi, L. S., Ambrosi, A., Ponzoni, M., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37630 · Cited by 571
Engelen, M., Kemp, S., de Visser, M., van Geel, B. M., Wanders, R. J., Aubourg, P., & Poll-The, B. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-51 · Cited by 562
Research works printed but not linked: 1
- Raymond GV Moser AB Fatemi A. X-linked adrenoleukodystrophy. In: Adam MP Feldman J Mirzaa GM et al. eds. GeneReviews. Seattle: University of Washington 1993 (http://www.ncbi.nlm.nih.gov/books/NBK1315/).
Cited by
Items 101–164 of 164
An Innovative Model for Cancer: Interdisciplinary Research Involving Biology and PsychologyPreprint
Huang, Q. (2025) · Preprints.org · doi:10.20944/preprints202502.0321.v1
Rossi, A., & Brunetti‐Pierri, N. (2025) · Clinical and Translational Discovery · doi:10.1002/ctd2.70038
The bleeding edge: broadening horizons for hematopoietic stem cell therapies
Shelton, S. D., & Sankaran, V. G. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.03.003
Response to: Safety and efficacy considerations of HSC-based gene therapy for RAG1-deficient SCID
Montini, E., Naldini, L., Booth, C., Kohn, D. B., & Aiuti, A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.049
Diagnosis of chronic myeloid neoplasms and approach to germline predisposition in children
Parisi, X., & Bledsoe, J. R. (2025) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2025.07.002
Self-citationPluripotent stem cell-based therapy toward the clinic for muscular dystrophy
Escobar, H. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.09.014
Köhler, W. (2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21344-1.00011-7
Inborn errors of metabolism and osteopetrosis
Fernandes, J. F., Rodrigues, A. M., Daudt, L. E., Klinger, P. H. D. S., & Bonfim, C. (2025) · JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY · doi:10.46765/2675-374x.2025v6n1e297
Decorin-expressing oncolytic herpes simplex virus vector for novel cancer therapy
Frejborg, F. (2025) · Doria (University of Helsinki)
SAGA-Q: Gene Expression Differences Enable Detection of Retroviral Vectors with Mutagenic Potential
Mansel, F., Bastone, A. L., John-Neek, P., Fleischauer, J., Dziadek, V., Hagedorn, M., Schambach, A., & Rothe, M. (2026) · Human Gene Therapy · doi:10.1177/10430342251396966
Huang, Q. (2026) · Preprints.org · doi:10.20944/preprints202502.0321.v2
Lee, N. C. J., Miao, R., & Young, N. S. (2026) · Leukemia · doi:10.1038/s41375-026-02865-x
Liu, X., Zhang, Q., Xu, H., Zhou, B., Luo, Z., Zhang, H., Wang, G., & Zhou, F. (2026) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(26)61102-8
Carrillo, M. A., Tomer, S., Wang, L., Cook, E., Wennerberg, W., Tien, N., Ng, H., Alagarsamy, J., Rezek, V. K., Martin, H. A., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.03.008
Asgarian, Z. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.02.047
Pretreatment blood NfL indicates response to cellular therapies in cerebral adrenoleukodystrophy
Weinhofer, I., Ponleitner, M., Rommer, P. S., Bergner, C. G., Starke, S., Gräfe, D., Merkenschlager, A., Forss‐Petter, S., Köhler, W., Berger, J., et al. (2026) · Communications Medicine · doi:10.1038/s43856-026-01525-6
Self-citationLuo, J., Zhao, F., Lin, S., & Liu, Y. (2026) · Medical Review · doi:10.1515/mr-2025-0082
Koueik, J., & Seroogy, C. M. (2026) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2026.02.009
Shelkowitz, E., Vergano, S. A. S., Penon‐Portmann, M., Wixson, G., Beckman, E., Campbell, T., Mills, M. R., Kochhar, A., Wilfond, B. S., Trowbridge, A. C., et al. (2026) · Genetics in Medicine · doi:10.1016/j.gim.2026.102581
Kuo, C. Y., Harrington, S., Campo-Fernández, B., Wyman, S. K., Wu, X., Zhang, R., Espinoza, A., Silva, B. J. D. A., Sanchez, J. M., Fitz‐Gibbon, S. T., et al. (2026) · Stem Cell Research & Therapy · doi:10.1186/s13287-026-05010-8
Self-citationSelezneva, A. V., Sosnovtseva, A. O., Starodubova, E. S., Antonov, D. O., Barkovskaya, V. I., & Киселев, С. Л. (2026) · Russian Journal of Genetics · doi:10.1134/s1022795425701741
Pediatric X-linked adrenoleukodystrophy: phenotypes, variants, and HSCT outcomes
Li, J., Ying, L., Chang, G., Ding, Y., Yu, T., Chen, J., & Wang, X. W. (2026) · European Journal of Pediatrics · doi:10.1007/s00431-026-06951-1
Gene therapy for liver diseases: methods, challenges and opportunities
Yan, M., & Xiang, Q. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04518-8
Ghosh, D., Mayer-Hamblett, N., & Kaizer, A. M. (2026) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2026.2667329
Samsonov, A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.15.725377
Liu, B., Klatt, D., Harris, C. E., McGuinness, M. K., Brendel, C., & Williams, D. A. (2026) · Nucleic Acids Research · doi:10.1093/nar/gkag500
Self-citationThe Journey of Gene Therapy in Sickle Cell Disease: How Molecular Advances Meet Clinical Care
Tardif, M., Saby, M., Forté, S., & Pincez, T. (2026) · Cells · doi:10.3390/cells15100939
González‐Nieto, D., Pérez‐Rigueiro, J., Rojo, F. J., Panetsos, F., & Guinea, G. V. (2026) · Gels · doi:10.3390/gels12060486
The future of hematopoietic stem cell and stem cell gene therapy for metabolic diseases
Vijayasekharan, K., Donald, A., Ghosh, A., & Wynn, R. F. (2026) · Regenerative Medicine · doi:10.1080/17460751.2026.2681399
Scalisi, G., Sakkal, A., Lacombe, L., Sarnari, F., Rouillon, M., Rosiello, M., Tachtsidi, A., Galbiati, P., Corre, G., Oustelandt, J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.15.732298
A novel ABCD1 frameshift mutation detected in a Chinese male with adrenomyeloneuropathy
Zhao, C., Li, Y., Tao, T., Zhang, Y., Zhang, G., & Yang, F. (2026) · Neurological Sciences · doi:10.1007/s10072-026-09191-1
Oncogenesis as an Adverse Effect of Gene Replacement Therapy in Hematopoietic Stem Cells
Petrova, I. O., & Smirnikhina, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146098
Joshi, G., Natarajan, N., Dickerson, K. E., & Voit, R. A. (2026) · British Journal of Haematology · doi:10.1111/bjh.70675
Gene therapy approaches for inborn errors of immunity: from bench to bedside
Dara, J., & Booth, C. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2710870
Wantuch, S., Tuske, S. J., Benedetti, S., Mehta, N., Brudvig, J. J., Do, H., Gotschall, R. R., Feng, J., Gaspar, A. B., Recchi, C., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201824
Mak, C. M., Wu, H. Y., Wong, A. Y., Song, F. E., Chan, T. C. H., Fung, C. W., Wong, S.-N. S., Hau, E. W. L., & Yeung, M. C. W. (2026) · International Journal of Neonatal Screening · doi:10.3390/ijns12030063
Yıldız, Y., & Haliloğlu, G. (2026) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2026.07.010
Wagenmakers, M., Lehman, A., den Hoed, C. M., van Dussen, L., Langeveld, M., & Sirrs, S. M. (2026) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-026-04377-4
Prete, A. D., Duran-Jimenez, B., & Black, A. (2026) · Human Gene Therapy · doi:10.1177/10430342261473434
Gene therapy: The current trajectory of clinical and commercial translation
Gibson, J. R., & Cottle, R. N. (2026) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2026.08.002
Baumgartner, F., Dickinson, M. J., & Blombery, P. A. (2026) · Blood · doi:10.1182/blood.2026033477
Syncytium-forming HSV-1 in cancer gene therapy: From molecular mechanisms to clinical translation
Zhao, X., Zhang, H., Xu, S., Mei, L., Feng, Z., Wang, D., Huang, W., & Shen, Y. (2026) · Virulence · doi:10.1080/21505594.2026.2721822
Making space for cures: Conditioning for autologous hematopoietic stem cell gene therapies
Crees, Z. D., DiPersio, J. F., & Persaud, S. P. (2026) · Seminars in Hematology · doi:10.1053/j.seminhematol.2026.09.001
Biologic Therapies for Alleviating Neurodegeneration in Lysosomal Storage Diseases
Qiu, L., Ungerbäck, J., Bennett, E., & Bak, R. O. (2026) · BioDrugs · doi:10.1007/s40259-026-00804-x
Gene therapy in leukodystrophies
Vafadar, A., Heidari, Z., & Savardashtaki, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40467-2.00010-5
Graham, J. P., Wheeler, E. E., Leach, K. J., & Gonzalez‐Fernandez, T. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.18.751510
A review of genetic modification for ex vivo cellular therapies
Dinh, A., Zhang, N., & Stroncek, D. F. (2026) · Transfusion · doi:10.1111/trf.70163
Furuta, Y., Li, H., Keller, S. R., Phillips, J. A., Tinker, R. J., Asano, E., & Juhász, C. (2026) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.70313
Evolution of Gene Therapy in Hematology
Loves, R. H., & Kohn, D. B. (2026) · Seminars in Hematology · doi:10.1053/j.seminhematol.2026.09.005
Gene therapy for hemoglobinopathies
Gibson, N. M., Patel, J., & Kwiatkowski, J. L. (2026) · Seminars in Hematology · doi:10.1053/j.seminhematol.2026.09.014
Liu, S., Feng, X.-M., Chen, Z., Chen, Z.-Q., Shang, Y.-R., Linnebacher, M., Wang, Y.-X., Zhang, S.-S., Cai, M., & Zhang, L. (2026) · World Journal of Clinical Oncology · doi:10.5306/wjco.126647
Evaluation of Anti-HIV-1 HSPC-Based Gene Therapy with Negative Selection Marker in Pigtail Macaques
Zhang, J., Murray, J., Mu, W., Venugopal, S., Yim, E., Einhaus, T., Radtke, S., Peterson, C. W., Kiem, H., & An, D. S. (2026) · Viruses · doi:10.3390/v18101133
Elp1 is required for myeloid differentiation and brain repopulation
Mader, M. M.-D., Li, W., Scavetti, A., Yoo, Y., Neumayer, G., Han, K., Shibuya, Y., Haney, M. S., Wyss‐Coray, T., George, L., et al. (2026) · Nature · doi:10.1038/s41586-026-11112-3
Gene Therapy for Osteoarthritis: Viral and Non-Viral Delivery Strategies
Zhang, M., Mohess, J., Cheung, J., Du, Q., Qiu, J., & Wang, J. (2026) · Viruses · doi:10.3390/v18101151
He, Z., McDaniel, J., Tian, L., Mohiuddin, M., Xu, N., Wang, L., Lin‐Gibson, S., Zook, J. M., & He, H. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201873
Fleischauer, J., Rothe, M., Ha, T. C., & Schambach, A. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2753949
Gene Therapy for Inherited Platelet Disorders
Ojeda-Walzuk, P. M., Marín‐Quilez, A., Torres, R., & Rivera, J. (2026) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2026.09.016
Olm, F., Kortleven, P., Mittendorfer, M., Carlon, M. S., Ceulemans, L. J., & Lindstedt, S. (2026) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2026.10.021
Abdelnabi, H., Alkaabi, S. M., Alderei, K. S., Alaryani, A. S., & Mohsin, S. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103808
McManus, M. L., Anstett, K., Lee, W.-Y., Shi, Y., Vitte, J., Chua, G. N., Brainin, R., Caulin, A., Erickson, G., Fisher, M. J., et al. (2026) · Genetics in Medicine Open · doi:10.1016/j.gimo.2026.104515
Programming immunity in situ: A new frontier of in vivo cell engineering
Mietz, J., Merlotti, A., de Fougerolles, A., Demaria, O., & Vivier, É. (2026) · Science Immunology · doi:10.1126/sciimmunol.aed1027
Metadata
- Authors
- Duncan, C. N., Bledsoe, J. R., Grzywacz, B., Beckman, A., Bonner, M., Eichler, F. S., Kühl, J.-S., Harris, M. H., Slauson, S., Colvin, R. A., Prasad, V. K., Downey, G. F., Pierciey, F. J., Kinney, M. A., Foos, M., Lodaya, A., Floro, N., Parsons, G., Dietz, A. C., Gupta, A. O., Orchard, P. J., Thakar, H. L., & Williams, D. A.
- Affiliations
- Boston Children's Hospital (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-10-10
- Volume
- 391
- Issue
- 14
- Pages
- 1287-1301
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC11846662
- OpenAlex
- W4403262140
- Cited by
- 164
- References
- 36
- Citations by year
- 2026: 76 · 2025: 72 · 2024: 15
- FWCI
- 32.80
- Type
- journal article
- Language
- en
- Open access
- green
- pmc.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- Funders
- Bluebird Bio
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- cerebral adrenoleukodystrophy, gene therapy, hematologic malignancies, myelodysplastic syndrome, acute myeloid leukemia, EVI1, MECOM, PRDM16, somatic mutations, monosomy 7, allogeneic hematopoietic stem cell transplantation
- MeSH terms
- ATP Binding Cassette Transporter, Subfamily D, Member 1, Adolescent, Adrenoleukodystrophy, Child, Female, Follow-Up Studies, Genetic Vectors, Humans, Male, Myelodysplastic Syndromes, Genetic Therapy, Lentivirus, Hematologic Neoplasms, Clonal Evolution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
